Is prostate-specific antigen still the best tumor marker for prostate cancer?

Simple item page
dc.contributor.authorLeewansangtong, Sen_US
dc.contributor.authorSoontrapa, Sen_US
dc.contributor.authorTantiwong, Aen_US
dc.date.accessioned2009-05-27T19:01:51Z
dc.date.available2009-05-27T19:01:51Z
dc.date.issued1999-10-24en_US
dc.descriptionChotmaihet Thangphaet. 54 references.en_US
dc.description.abstractPSA has been utilized for more than a decade. Since the overwhelming benefit of PSA, the previous markers for prostate cancer have been abandoned. Even though PSA is no more an organ specific agent, its function as an organ specific marker remains in all clinical situations. PSA is significantly involved not only in screening for early detection but also in all clinical spectrums of prostate cancer. Never before has the tumor marker played such a significant role in all purposes of clinical utilization for prostate cancer as PSA has. The answer to the title of this article is absolutely positive. Nevertheless, the following question of whether PSA has an impact in decreasing the mortality rate of patients with prostate cancer is yet to be answered. In Siriraj Hospital, though PSA has been available since 1991, the majority of patients registered with the advanced stage of disease and their treatment outcomes are not always satisfactory. Since the prognoses of the patients with an early stage of disease appear very good, to improve the mortality of Thai patients with prostate cancer, screening using PSA for early detection should be introduced and widely used.en_US
dc.description.affiliationDepartment of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.en_US
dc.identifier.citationLeewansangtong S, Soontrapa S, Tantiwong A. Is prostate-specific antigen still the best tumor marker for prostate cancer? Journal of the Medical Association of Thailand. 1999 Oct; 82(10): 1034-40en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/40331
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAgeden_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMolecular Weighten_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProstate-Specific Antigen --blooden_US
dc.subject.meshProstatic Neoplasms --blooden_US
dc.subject.meshTumor Markers, Biological --blooden_US
dc.titleIs prostate-specific antigen still the best tumor marker for prostate cancer?en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand